News stories about Calyxt (NASDAQ:CLXT) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Calyxt earned a news impact score of 0.05 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.5764984030822 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Comparing Calyxt (CLXT) and Its Competitors (americanbankingnews.com)
- Calyxt Exceeds Farmer Adoption Milestone for High-Oleic Soybean Product Launch (finance.yahoo.com)
- Calyxt (CLXT) Receives New Coverage from Analysts at BMO Capital Markets (americanbankingnews.com)
- Calyxt (CLXT) and Its Competitors Head-To-Head Contrast (americanbankingnews.com)
- Reviewing Calyxt (CLXT) and Its Rivals (americanbankingnews.com)
Several research firms have issued reports on CLXT. Zacks Investment Research downgraded Calyxt from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Ladenburg Thalmann Financial Services began coverage on Calyxt in a report on Wednesday, December 20th. They set a “buy” rating and a $34.25 price objective on the stock. Jefferies Group restated a “buy” rating and set a $27.00 price objective on shares of Calyxt in a report on Thursday, March 1st. Finally, ValuEngine upgraded Calyxt from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.05.
In other news, insider Manoj Sahoo sold 10,780 shares of Calyxt stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $19.87, for a total value of $214,198.60. Following the completion of the transaction, the insider now owns 95,146 shares in the company, valued at approximately $1,890,551.02. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Daniel F. Voytas sold 4,666 shares of Calyxt stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $17.91, for a total value of $83,568.06. Following the completion of the transaction, the insider now owns 4,666 shares of the company’s stock, valued at approximately $83,568.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,496 shares of company stock valued at $2,045,928.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, enhanced oil composition and herbicide tolerant canola, enhanced quality and herbicide tolerant alfalfa, late blight resistant potatoes, and cold storable/reduced browning potatoes, as well as enhanced protein composition, drought tolerant, herbicide tolerant, and enhanced yield soybeans.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.